I-124 PET Directed Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer: the I-FIRST Study: Difference between revisions
Jump to navigation
Jump to search
wikispore>Pkdilena (Created page with "{{item |type_parameter=research |description_parameter=For patients with advanced thyroid cancer, tumours that no longer trap radioiodine have an extremely poor prognosis and more effective treatments are urgently required. This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life. |aim_parameter={{aim parameter|This study will examine whether redifferentiation therap...") |
wikispore>Pkdilena No edit summary |
||
| Line 8: | Line 8: | ||
|location_parameter=Australia | |location_parameter=Australia | ||
|location_link=No | |location_link=No | ||
|author_parameter={{author parameter | |||
|aut_nam=Portia Dilena | |||
|aut_url=https://scholars.latrobe.edu.au/pdilena | |||
|aut_con=non contact | |||
}} | |||
|contributor_parameter={{contributor parameter | |contributor_parameter={{contributor parameter | ||
|con_typ=individual | |con_typ=individual | ||
| Line 13: | Line 18: | ||
|con_tas=Lead Chief Investigator | |con_tas=Lead Chief Investigator | ||
|con_url=https://www.onjcri.org.au/about-us/andrew-scott/ | |con_url=https://www.onjcri.org.au/about-us/andrew-scott/ | ||
|con_cop= | |con_cop=paid | ||
|con_dates=No | |con_dates=No | ||
}} | }} | ||
| Line 19: | Line 24: | ||
|inp_typ=funding | |inp_typ=funding | ||
|inp_inp=2,708,660.70 | |inp_inp=2,708,660.70 | ||
|inp_currency=AUD | |||
}} | }} | ||
}} | }} | ||
Revision as of 05:36, 27 March 2023
Description: For patients with advanced thyroid cancer, tumours that no longer trap radioiodine have an extremely poor prognosis and more effective treatments are urgently required. This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life.
Dates
State ongoing
Start 2021-01-01
End 2026-01-01
Form updated 2023-03-27
Report authors
Portia Dilena (link)
Location
Australia
Aims
This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life
. We will also determine the affordability of bringing this therapy to the clinic
Category
research
Inputs
funding
2,708,660.70 (AUD)